Current Research: Pediatric Hematology-Oncology

ABTR06C1 -- Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer

Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

This laboratory study is looking at the pharmacokinetics of daunorubicin in treating young patients with cancer.

Eligibility

Patients may be eligible for this trial if:

• Patients must be ≤ 21 years of age at the time of study entry.
• Patients with any diagnosis of a malignancy are eligible.
• All patients must be receiving chemotherapy that includes daunomycin administered as an infusion of any duration < 24 hours on either a 1- or a 2-day schedule. This includes bolus and all short infusion schedules. The concomitant chemotherapy a patient may be getting does not affect eligibility. The patient does not have to be registered on a COG treatment study to be eligible for this study.
• There are no organ function requirements for this study as the decision whether or not to administer daunomycin is not part of this protocol.

Exclusion Criteria

• Women who are pregnant or breast-feeding.
• Patients with significant uncontrolled systemic illness.
• Patients with large implanted prostheses that would interfere with the DXA scan.

Trial Sponsor

• Children’s Oncology Group (COG); National Cancer Institute (NCI)

Project Begin Date

• Aug 2007

Tentative Project End Date

• Ongoing

Back to Pediatric Hematology-Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .